Pseudomembranous colitis and toxic megacolon due to C. difficile in an inpatient hospitalized for home accident
DOI:
https://doi.org/10.7175/cmi.v9i1S.1158Keywords:
Pseudomembranous colitis, Toxic megacolon, Clostridium difficile, Trauma, FidaxomicinAbstract
Clostridium difficile infection (CDI) is the main cause of hospital-acquired diarrhea. It can result in symptoms ranging from moderate diarrhea to pseudomembranous colitis. Among the risk factors, there is antibiotic therapy, responsible for intestinal flora disruption.
A 72-year-old man presented to the Emergency Room for a home accident, a fall, that resulted in a cranio-facial trauma and tibio-tarsal fracture. He was administered cefazolin. Then he underwent surgery and the antibiotic therapy was switched to teicoplanin + levofloxacin; three days after, he started having diarrhea and mild fever. Rifaximin was added. A further exacerbation prompted the replacement of antibiotic therapy with tazobactam-piperacillin and metronidazole. Owing to the detection in fecal examination of CDI signs, tazobactam-piperacillin were replaced with vancomicin. Due to the persistence of symptoms, the worsening of physical conditions and the onset of pseudomembranous colitis and toxic megacolon, fidaxomicin therapy was started, with symptom resolution in few days. A patient’s follow-up at five months post-treatment showed no CDI recurrence.
References
Elliott B, Chang BJ, Golledge CL, et al. Clostridium difficile-associated diarrhoea. Intern Med J 2007; 37: 561-8; http://dx.doi.org/10.1111/j.1445-5994.2007.01403.x
McFarland LV. Update on the changing epidemiology of Clostridium difficile-associated disease. Nat Clin Pract Gastroenterol Hepatol 2008; 5: 40-8; http://dx.doi.org/10.1038/ncpgasthep1029
Aldeyab MA, Harbarth S, Vernaz N, et al. Quasi experimental study of the effects of antibiotic use, gastric acid-suppressive agents, and infection control practices on the incidence of Clostridium difficile-associated diarrhea in hospitalized patients. Antimicrob Agents Chemother 2009; 53: 2082-8; http://dx.doi.org/10.1128/AAC.01214-08
Thomas C, Stevenson M, Riley TV. Antibiotics and hospital-acquired Clostridium difficile-associated diarrhoea: a systematic review. J Antimicrob Chemother 2003; 51: 1339-50; http://dx.doi.org/10.1093/jac/dkg254
Vernaz N, Hill K, Leggeat S, et al. Temporal effects of antibiotic use and Clostridium difficile infections. J Antimicrob Chemother 2009; 63: 1272-5; http://dx.doi.org/10.1093/jac/dkp128
Owens RC Jr, Donskey CJ, Gaynes RP, et al. Anti-microbial-associated risk factors for Clostridium difficile infection. Clin Infect Dis 2008; 46 (Suppl. 1): S19-S31; http://dx.doi.org/10.1086/521859
Pépin J, Saheb N, Coulombe MA, et al. Emergence of fluoroquinolones as the pre-dominant risk factor for Clostridium difficile-associated diarrhea: a cohort study during an epidemic in Quebec. Clin Infect Dis 2005; 41: 1254-60; http://dx.doi.org/10.1086/496986
Debast SB, Bauer MP, Kuijper EJ. European Society of Clinical Microbiology and Infectious Diseases: update of the treatment guidance document for Clostridium difficile infection. European Society of Clinical Microbiology and Infectious Diseases. Clin Microbiol Infect 2014; 20 (Suppl 2): 1-26; http://dx.doi.org/10.1111/1469-0691.12418; http://dx.doi.org/10.1111/1469-0691.12418
Drekonja DM, Butler M, MacDonald R, et al. Comparative effectiveness of Clostridium difficile treatments: a systematic review. Ann Intern Med 2011; 155: 839-47; http://dx.doi.org/10.7326/0003-4819-155-12-201112200-00007
Cornely OA, Crook DW, Esposito R, et al; OPT-80-004 Clinical Study Group. Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double-blind, non-inferiority, randomised controlled trial. Lancet Infect Dis 2012; 1-9; http://dx.doi.org/10.1016/S1473-3099(11)70374-7
Wilcox MH. Progress with a difficult infection. Lancet Infect Dis 2012; 12: 256-7; http://dx.doi.org/10.1016/S1473-3099(12)70013-0
Published
Issue
Section
License
Authors who publish with this journal agree to the following terms:- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution Non-Commercial 4.0 Licence that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal. The Publication Agreement can be downloaded here, and should be signed by the Authors and sent to the Publisher when the article has been accepted for publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
- Authors are permitted to post their work online after publication (the article must link to publisher version, in html format)